Viatris Inc (VTRS)
Viatris Inc (VTRS) from its SEC filings: 2025 revenue $14.3 billion (-3% vs the year before), free cash flow $1.9 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $14.3 billion |
| Revenue growth | -3% |
| Free cash flow | $1.9 billion |
| Diluted EPS | $-3.00 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +5% |
| Cash | $886.5 million |
| Long-term debt | $11.6 billion |
| Share count, 1 year | -2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.